Kcentra® (Prothrombin Complex Concentrate [Human]): Its indications, side effects, and contraindications
Abstract
Patients with a high risk for thromboembolic events can be on long-term warfarin. These patients need close monitoring of their INR and for signs of bleeding. Conventionally, fresh frozen plasma (FFP) is used for reversal of INR in patients with major bleeding or who need urgent surgery or invasive procedures. Kcentra is now available as an alternative to FFP for rapid reversal of INR and urgent hemostasis.
Keywords: Kcentra, four factor prothrombin complex concentrate, acute major bleeding, urgent hemostasis, INR reversal, warfarin
Downloads
References
KCENTRA (package insert). Kankakee, IL: CSL Behring;
Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant
therapy: Antithrombotic Therapy and Prevention of
Thrombosis, 9th ed: American College of Chest Physicians
Evidence-Based Clinical Practice Guidelines. Chest 2012
Feb;141(2 Suppl):e44S–e88S.
Pandey S, Vyas GN. Adverse effects of plasma transfusion.
Transfusion 2012 May; 52 Suppl 1:65S–79S.
Theusinger OM et al. Point of Care and Factor Concentrate-
Based Coagulation Algorithms. Transfus Med Hemother
Mar;42(2):115–121.
Schulman S, Bijsterveld NR. Anticoagulants and their reversal.
Transfus Med Rev 2007;21(1):37–48.
Sarode R, Milling TJ, Refaai MA, et al. Efficacy and safety
of a 4-factor prothrombin complex concentrate in patients
on vitamin K antagonists presenting with major bleeding: a
randomized, plasma-controlled, phase IIIb study. Circulation
;128:1234–43.
Goldstein JN, Refaai MA, Milling TJ Hr, et al. Four-factor
prothrombin complex concentrate versus plasma for rapid
vitamin K antagonist reversal in patients needing urgent
surgical or invasive interventions: a phase 3b, open-label,
non-inferiority, randomized control study. Lancet 2015 May
;385(9982):2077–87.
